PMN.TO - ProMIS Neurosciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.21
+0.00 (+2.44%)
At close: 3:53PM EST
Stock chart is not supported by your current browser
Previous Close0.20
Open0.22
Bid0.20 x 0
Ask0.21 x 0
Day's Range0.21 - 0.22
52 Week Range0.14 - 0.35
Volume68,000
Avg. Volume197,617
Market Cap46.212M
Beta-0.66
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateMar 13, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
  • ProMIS Neurosciences Announces Trading on OTCQB Venture Market
    CNW Group13 days ago

    ProMIS Neurosciences Announces Trading on OTCQB Venture Market

    TORONTO and CAMBRIDGE, MA, Dec. 4, 2017 /CNW/ - ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (OTCQB) in the United States under the symbol "ARFXF". OTCQB is a U.S. trading platform operated by the OTC Markets Group in New York.  ProMIS Neurosciences common shares will continue to trade on the Toronto Stock Exchange (TSX:PMN.TO - News).

  • ProMIS Neurosciences Announces Trading on OTCQB Venture Market
    PR Newswire13 days ago

    ProMIS Neurosciences Announces Trading on OTCQB Venture Market

    TORONTO and CAMBRIDGE, MA, Dec. 4, 2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (OTCQB) in the United States under the symbol "ARFXF". OTCQB is a U.S. trading platform operated by the OTC Markets Group in New York.  ProMIS Neurosciences common shares will continue to trade on the Toronto Stock Exchange (PMN.TO).

  • GlobeNewswire13 days ago

    ProMIS Neurosciences Announces Trading on OTCQB Venture Market

    TORONTO and CAMBRIDGE, Mass., Dec. 04, 2017-- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that ...

  • GlobeNewswire24 days ago

    Streetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug Candidate 

    SAN FRANCISCO, Nov. 23, 2017-- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.. Included ...

  • ACCESSWIRElast month

    Report Coverage on Healthcare Stocks, ProMIS Neurosciences, Spectral Medical, GeneNews, and Sernova

    LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...

  • ProMIS Neurosciences Announces Third Quarter 2017 Results
    PR Newswirelast month

    ProMIS Neurosciences Announces Third Quarter 2017 Results

    TORONTO and CAMBRIDGE, MA, Nov. 13, 2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2017. Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO stated: "With the successful private placement in Q3 2017 supporting a cash runway into the second half of 2018, we continue to focus on the company's top priorities.  In this regard, we look forward to further advancing the development of our lead product candidates for Alzheimer's disease with particular emphasis on the ongoing preclinical program to differentiate our leads compared to competitive antibody products in development.

  • ProMIS Neurosciences Announces Third Quarter 2017 Results
    CNW Grouplast month

    ProMIS Neurosciences Announces Third Quarter 2017 Results

    TORONTO and CAMBRIDGE, MA, Nov. 13, 2017 /CNW/ - ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2017. Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO stated: "With the successful private placement in Q3 2017 supporting a cash runway into the second half of 2018, we continue to focus on the company's top priorities.  In this regard, we look forward to further advancing the development of our lead product candidates for Alzheimer's disease with particular emphasis on the ongoing preclinical program to differentiate our leads compared to competitive antibody products in development.

  • GlobeNewswirelast month

    ProMIS Neurosciences Announces Third Quarter 2017 Results

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 13, 2017-- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today ...

  • ProMIS Neurosciences Provides Third Quarter Update for 2017
    CNW Group2 months ago

    ProMIS Neurosciences Provides Third Quarter Update for 2017

    Updated corporate overview available on ProMIS website TSX: PMN TORONTO and CAMBRIDGE, MA , Oct. 11, 2017 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development ...

  • ProMIS Neurosciences Provides Third Quarter Update for 2017
    PR Newswire2 months ago

    ProMIS Neurosciences Provides Third Quarter Update for 2017

    TORONTO and CAMBRIDGE, MA, Oct. 11, 2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the third quarter of 2017, including key accomplishments and a status update on ongoing programs.

  • GlobeNewswire2 months ago

    ProMIS Neurosciences Provides Third Quarter Update for 2017

    TORONTO and CAMBRIDGE, Mass., Oct. 11, 2017-- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today ...

  • ACCESSWIRE2 months ago

    Daily Coverage on Healthcare Stocks ProMIS Neurosciences Spectral Medical GeneNews and Sernova

    LONDON, UK / ACCESSWIRE / October 9, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...

  • Baystreet3 months ago

    Stocks in play: ProMIS Neurosciences, Inc.

    Announced the successful humanization of its lead product candidate for Alzheimer's disease, PMN310, ...